Skip to content

Study · Animal study (in vivo) · mouse · 2018

8 results

AICAR Prevents Acute Olanzapine-Induced Disturbances in Glucose Homeostasis.

Bush ND, Townsend LK, Wright DC

The Journal of pharmacology and experimental therapeutics26 Mar 2018Cited by 19 (Europe PMC)

PMID29581153 (opens in a new tab)DOI10.1124/jpet.118.248393 (opens in a new tab)PepBankPUB-29581153
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In lean and obese mice, AICAR prevented olanzapine-induced blood glucose increases.

    In plain wordsIn lean and obese mice, AICAR prevented blood sugar increases compared with olanzapine alone.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseHyperglycemia
    Study

    mousen: not reported in source

    Lean and obese C57BL6/J mice challenged with olanzapine
    Comparator
    Olanzapine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    OLZ (5 mg/kg, i.p.) caused rapid increases in blood glucose, a blunted insulin response, and pyruvate intolerance, all of which were prevented with AICAR cotreatment in both lean and obese mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In lean and obese mice, AICAR prevented the blunted insulin response caused by olanzapine.

    In plain wordsIn lean and obese mice, AICAR preserved the insulin response compared with olanzapine alone.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseInsulin response
    Study

    mousen: not reported in source

    Lean and obese C57BL6/J mice challenged with olanzapine
    Comparator
    Olanzapine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    OLZ (5 mg/kg, i.p.) caused rapid increases in blood glucose, a blunted insulin response, and pyruvate intolerance, all of which were prevented with AICAR cotreatment in both lean and obese mice.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In lean and obese mice, AICAR prevented olanzapine-induced pyruvate intolerance.

    In plain wordsIn lean and obese mice, AICAR prevented pyruvate intolerance compared with olanzapine alone.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreasePyruvate intolerance
    Study

    mousen: not reported in source

    Lean and obese C57BL6/J mice challenged with olanzapine
    Comparator
    Olanzapine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    OLZ (5 mg/kg, i.p.) caused rapid increases in blood glucose, a blunted insulin response, and pyruvate intolerance, all of which were prevented with AICAR cotreatment in both lean and obese mice.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice, AICAR did not affect olanzapine-induced changes in whole-body substrate oxidation.

    In plain wordsIn mice, AICAR did not change the effects of olanzapine on whole-body substrate oxidation.

    Peptide
    AICAR (acadesine)
    Outcome
    No significant changeWhole-body substrate oxidation
    Study

    mousen: not reported in source

    Lean and obese C57BL6/J mice challenged with olanzapine
    Comparator
    Olanzapine alone
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    AICAR did not affect OLZ-induced changes in whole-body substrate oxidation or energy expenditure.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice, AICAR did not affect olanzapine-induced changes in energy expenditure.

    In plain wordsIn mice, AICAR did not change the effects of olanzapine on energy expenditure.

    Peptide
    AICAR (acadesine)
    Outcome
    No significant changeEnergy expenditure
    Study

    mousen: not reported in source

    Lean and obese C57BL6/J mice challenged with olanzapine
    Comparator
    Olanzapine alone
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    AICAR did not affect OLZ-induced changes in whole-body substrate oxidation or energy expenditure.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice, peripheral AICAR activated hypothalamic AMPK signaling, whereas olanzapine did not.

    In plain wordsIn mice, peripheral AICAR activated hypothalamic AMPK signaling, whereas olanzapine did not.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseHypothalamic AMPK signaling
    Study

    mousen: not reported in source

    Lean and obese C57BL6/J mice challenged with olanzapine
    Comparator
    Olanzapine
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated · peripheral injectionAs given in this study (mouse).

    Source sentences

    Summary
    Peripheral injection of AICAR, but not OLZ, activated AMPK signaling in the hypothalamus.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In olanzapine-treated mice, AICAR protection was associated with preserved whole-body insulin action.

    In plain wordsIn olanzapine-treated mice, AICAR protection was associated with preserved insulin action.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseWhole-body insulin action
    Study

    mousen: not reported in source

    Lean and obese C57BL6/J mice challenged with olanzapine
    Comparator
    Olanzapine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These protective effects were associated with the preservation of whole-body insulin action and reductions in markers of liver glucose production.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In olanzapine-treated mice, AICAR protection was associated with reduced markers of liver glucose production.

    In plain wordsIn olanzapine-treated mice, AICAR protection was associated with lower markers of liver sugar production.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseLiver glucose production markers
    Study

    mousen: not reported in source

    Lean and obese C57BL6/J mice challenged with olanzapine
    Comparator
    Olanzapine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These protective effects were associated with the preservation of whole-body insulin action and reductions in markers of liver glucose production.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.